Comparison of the Three Months ended April 1, 2023 and April 2, 2022
Revenue
In the three months ended April 1, 2023, revenue increased by $64 million, or 16%, compared to the three months ended April 2, 2022. This increase was primarily driven by an increase of $41 million, or 11%, in EyeQ® SoC revenue, and ramp up in sales of our SuperVision™ product. The increase in revenue is attributable to approximately 10% increase in volume of EyeQ® and SuperVision systems and to approximately 6% increase in Average System Price, which is calculated as the sum of revenue related to EyeQ® and SuperVision systems, divided by the number of systems delivered.
Cost of Revenue
In the three months ended April 1, 2023, our cost of revenue increased by $33 million, or 15%, compared to the three months ended April 2, 2022. This increase was primarily due to an increase of $41 million in manufacturing costs relating primarily to increased sales of our EyeQ® SoC and SuperVision™ systems, as well as to a rise in the cost of our EyeQ® SoCs due to the global semiconductor shortage and inflationary pressures, partially offset by a decrease of $9 million in amortization of intangible assets.
Gross Profit and margin
In the three months ended April 1, 2023, our gross profit increased by $31 million, or 18%, compared to the three months ended April 2, 2022. This increase was mainly driven by the increase in sales of both EyeQ® SoC and SuperVision™ systems.
Our gross margin was 45% in both the three months ended April 1, 2023 and the three months ended April 2, 2022, as the downward impact of the increased cost of our EyeQ® SoCs (which was passed through as a price increase to our customers on a zero-margin basis) was mostly offset by lower impact of the cost attributable to amortization of intangible assets as a percentage of revenue.
Research and Development Expenses, net
Research and development expenses, net, in the three months ended April 1, 2023, increased by $55 million, or 31%, compared to the three months ended April 2, 2022. This increase was primarily due to an increase of $43 million in payroll and related expenses, resulting from an increase in average research and development headcount of 480 employees and an increase in payroll costs, including an increase of $23 million in share-based compensation. The remaining increase is mainly related to occupancy and related expenses associated with the lease of new office space in additional sites.
Sales and Marketing Expenses
Sales and marketing expenses in the three months ended April 1, 2023, decreased by $2 million, or 6%, compared to the three months ended April 2, 2022. This decrease was mainly due to a decrease of $7 million in amortization of customer relationship and brand-related intangible assets, partially offset by an increase of $4 million in advertising and marketing expenses.
General and Administrative Expenses
General and administrative expenses in the three months ended April 1, 2023, increased by $13 million, or 186%, compared to the three months ended April 2, 2022. This increase was mainly due to an increase in payroll and related expenses, including an increase of $7 million in share-based compensation, as well as costs related to being a public company.
Interest Income (expense) with related party, net and Other Financial Income (expense), net
Other financial income (expense), net, in the three months ended April 1, 2023, was $8 million compared to $1 million in the three months ended April 2, 2022. This increase was mainly due to interest earned on investment in money market funds, as well as higher interest earned on short term bank deposits.
In the three months ended April 2, 2022, we generated interest income of $1 million on a loan to Intel which was fully repaid by Intel to us in December 2022.